Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Acetylsalicyclic acid · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Arm 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036) | DRUG | Single dose of fast acting aspirin 2 x 325 mg = 650 mg total |
| Acetylsalicyclic acid (Aspirin, BAYE4465) | DRUG | Single dose of regular aspirin 2 x 325 mg = 650 mg total |
| Placebo | DRUG | Two placebo tablets |
Inclusion Criteria: * Healthy, ambulatory, male and female volunteers between 16 to 45 years of age * Scheduled to undergo surgical removal of either two partial bony impactions or one full bony alone or in combination with a partial bony impaction, soft tissue impaction or erupted third molar. Max...
Acetylsalicyclic acid is a small molecule drug being developed by Bayer AG under the code BAY1019036. It is a fast release aspirin formulation studied as an investigational analgesic. The program has completed a Phase 3 trial evaluating its pain relief effects in 500 participants in the United States.
Acetylsalicyclic acid is being studied for analgesic use, meaning pain relief, in an investigational setting. The completed Phase 3 trial evaluated its analgesic efficacy as a fast release aspirin formulation. It is not described as an approved product for these investigational uses in the available program information.
Bayer AG develops acetylsalicyclic acid, which carries the company code BAY1019036. Bayer trades on the OTC market under the ticker BAYRY. The fast release aspirin program is listed as a Bayer investigational asset in the analgesic space.
Acetylsalicyclic acid is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active. The completed study, NCT01122602, was randomized, double blind, and placebo controlled, enrolling 500 participants in the United States.
Acetylsalicyclic acid has been studied in one completed Phase 3 trial, NCT01122602, titled Evaluate Analgesic Efficacy of Fast Release Aspirin. That randomized, double blind, placebo controlled study enrolled 500 participants in the United States, including healthy volunteers, with a minimum age of 16 years and both sexes eligible.
Yes. Acetylsalicyclic acid is also known as fast release aspirin and fast acting aspirin, both associated with the code BAY1019036. These names refer to the same Bayer investigational program, so searches for fast release aspirin or fast acting aspirin point to this same asset.